methylphenidate has been researched along with Bilateral Headache in 18 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Trials of amphetamines, atomoxetine, bupropion, clonidine, guanfacine, methylphenidate, and modafinil with a placebo arm and reporting data on headache as an adverse event, were included." | 2.82 | Headache in ADHD as comorbidity and a side effect of medications: a systematic review and meta-analysis. ( Banaschewski, T; Bölte, S; Buitelaar, JK; Coghill, D; Cortese, S; Häge, A; Hohmann, S; Jonsson, U; Nobel Norrman, H; Pan, PY; Şahpazoğlu Çakmak, SS, 2022) |
| "Bupropion has a comparable safety and efficacy profile with methylphenidate in children and adolescents with ADHD." | 2.77 | Bupropion versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: randomized double-blind study. ( Akhondzadeh, S; Ashrafi, M; Jafarinia, M; Khajavi, D; Modabbernia, A; Mohammadi, MR; Tabrizi, M; Yadegari, N, 2012) |
| " Dosing began at 36 mg/d, with titration in 18-mg increments every 7 days until a predefined outcome (efficacy threshold, maximum dosage of 108 mg/d, or limiting adverse event)." | 2.76 | Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: an open-label, dose-titration, 1-year study. ( Adler, LA; Berwaerts, J; Cooper, K; Harrison, DD; Orman, C; Palumbo, J; Silber, S; Starr, HL, 2011) |
| " Adverse events were monitored throughout the study period." | 2.73 | Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study. ( Brams, M; Mao, A; McCague, K; Muniz, R; Pestreich, L; Silva, R, 2008) |
| " Headache, anorexia, and insomnia were the most frequently reported treatment-related adverse events." | 2.72 | Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder. ( Bukstein, O; Greenhill, L; Lerner, M; McBurnett, K; McGough, JJ; Stein, M; Wilens, TE, 2006) |
| " The terminal half-life of methylphenidate was similar for the three formulations." | 2.69 | Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation. ( Gupta, SK; Lindemulder, B; Modi, NB, 2000) |
| "Methylphenidate (MPD) is a central nervous system (CNS) stimulant, which belongs to the phenethylamine group and is mainly used in the treatment of attention deficit hyperactive disorder (ADHD)." | 2.53 | From Clinical Application to Cognitive Enhancement: The Example of Methylphenidate. ( Busardò, FP; Cipolloni, L; Frati, P; Kyriakou, C; Zaami, S, 2016) |
| "Pharmacological treatment of attention deficit hyperactivity disorder (ADHD) includes stimulant and non-stimulant medications." | 1.42 | Combined methylphenidate and atomoxetine pharmacotherapy in attention deficit hyperactivity disorder. ( Atar, B; Aydin, C; Kose, S; Ozbaran, B; Yuzuguldu, O, 2015) |
| " Methylphenidate (MP) appears safe when used in the treatment of depression and fatigue in advanced cancer." | 1.36 | Methylphenidate side effects in advanced cancer: a retrospective analysis. ( Davis, MP; Khoshknabi, DS; Lasheen, W; Mahmoud, F; Rivera, N; Walsh, D, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (11.11) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 6 (33.33) | 29.6817 |
| 2010's | 7 (38.89) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Pan, PY | 1 |
| Jonsson, U | 1 |
| Şahpazoğlu Çakmak, SS | 1 |
| Häge, A | 1 |
| Hohmann, S | 1 |
| Nobel Norrman, H | 1 |
| Buitelaar, JK | 1 |
| Banaschewski, T | 1 |
| Cortese, S | 1 |
| Coghill, D | 1 |
| Bölte, S | 1 |
| Quinn, DK | 1 |
| Mayer, AR | 1 |
| Master, CL | 1 |
| Fann, JR | 1 |
| Ozbaran, B | 1 |
| Kose, S | 1 |
| Yuzuguldu, O | 1 |
| Atar, B | 1 |
| Aydin, C | 1 |
| Busardò, FP | 1 |
| Kyriakou, C | 1 |
| Cipolloni, L | 1 |
| Zaami, S | 1 |
| Frati, P | 1 |
| Findling, RL | 1 |
| Muniz, R | 1 |
| Brams, M | 1 |
| Mao, A | 1 |
| McCague, K | 1 |
| Pestreich, L | 1 |
| Silva, R | 1 |
| Lasheen, W | 1 |
| Walsh, D | 1 |
| Mahmoud, F | 1 |
| Davis, MP | 1 |
| Rivera, N | 1 |
| Khoshknabi, DS | 1 |
| Adler, LA | 1 |
| Orman, C | 1 |
| Starr, HL | 1 |
| Silber, S | 1 |
| Palumbo, J | 1 |
| Cooper, K | 1 |
| Berwaerts, J | 1 |
| Harrison, DD | 1 |
| Jafarinia, M | 1 |
| Mohammadi, MR | 2 |
| Modabbernia, A | 1 |
| Ashrafi, M | 1 |
| Khajavi, D | 1 |
| Tabrizi, M | 1 |
| Yadegari, N | 1 |
| Akhondzadeh, S | 1 |
| ROBERTS, HJ | 1 |
| Ghanizadeh, A | 1 |
| Alaghband-Rad, J | 1 |
| Tehranidoost, M | 1 |
| Mesgarpour, B | 1 |
| Soori, H | 1 |
| McGough, JJ | 1 |
| McBurnett, K | 1 |
| Bukstein, O | 1 |
| Wilens, TE | 1 |
| Greenhill, L | 1 |
| Lerner, M | 1 |
| Stein, M | 1 |
| Prasad, S | 1 |
| Harpin, V | 1 |
| Poole, L | 1 |
| Zeitlin, H | 1 |
| Jamdar, S | 1 |
| Puvanendran, K | 1 |
| Lechin, F | 1 |
| van der Dijs, B | 1 |
| Ahmann, PA | 1 |
| Waltonen, SJ | 1 |
| Olson, KA | 1 |
| Theye, FW | 1 |
| Van Erem, AJ | 1 |
| LaPlant, RJ | 1 |
| Modi, NB | 1 |
| Lindemulder, B | 1 |
| Gupta, SK | 1 |
| Barkley, RA | 1 |
| McMurray, MB | 1 |
| Edelbrock, CS | 1 |
| Robbins, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label, Dose-Titration, Long-Term Safety Study to Evaluate CONCERTA (Methylphenidate HCL) Extended-release Tablets at Doses of 36 mg, 54 mg, 72 mg, 90 mg, and 108 mg Per Day in Adults With Attention Deficit Hyperactivity Disorder[NCT00326300] | Phase 3 | 560 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for methylphenidate and Bilateral Headache
| Article | Year |
|---|---|
Headache in ADHD as comorbidity and a side effect of medications: a systematic review and meta-analysis.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2022 |
Aptensio XR--another long-acting methylphenidate.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-A | 2015 |
From Clinical Application to Cognitive Enhancement: The Example of Methylphenidate.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognition | 2016 |
Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; | 2008 |
9 trials available for methylphenidate and Bilateral Headache
| Article | Year |
|---|---|
Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study.
Topics: Attention Deficit Disorder with Hyperactivity; Chemistry, Pharmaceutical; Child; Cross-Over Studies; | 2008 |
Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: an open-label, dose-titration, 1-year study.
Topics: Adolescent; Adult; Age Factors; Aged; Attention Deficit Disorder with Hyperactivity; Delayed-Action | 2011 |
Bupropion versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: randomized double-blind study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Bupropion; Child; Dopamine Uptake Inhibit | 2012 |
Selegiline in comparison with methylphenidate in attention deficit hyperactivity disorder children and adolescents in a double-blind, randomized clinical trial.
Topics: Adolescent; Anorexia Nervosa; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Met | 2004 |
Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Anorexia; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2006 |
A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD).
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2007 |
Placebo-controlled evaluation of Ritalin side effects.
Topics: Adolescent; Appetite; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior; Child, P | 1993 |
Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Biological Availability; Central Nervous | 2000 |
Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; | 1990 |
5 other studies available for methylphenidate and Bilateral Headache
| Article | Year |
|---|---|
Prolonged Postconcussive Symptoms.
Topics: Accidents, Traffic; Adaptation, Psychological; Anxiety Disorders; Attention; Axons; Brain Concussion | 2018 |
Combined methylphenidate and atomoxetine pharmacotherapy in attention deficit hyperactivity disorder.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2015 |
Methylphenidate side effects in advanced cancer: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Akathisia, Drug-Induced; Anorexia; Central Nervous System Stimulants | 2010 |
THE SYNDROME OF NARCOLEPSY AND DIABETOGENIC (FUNCTIONAL) HYPERINSULINISM. OBSERVATIONS ON 190 PATIENTS, WITH EMPHASIS UPON ITS RELATIONSHIP TO OBESITY, DIABETES MELLITUS AND CEREBRAL DYSRHYTHMIAS.
Topics: Adolescent; Alcoholism; Arrhythmias, Cardiac; Brain; Diabetes Mellitus; Diet; Diet, Reducing; Electr | 1963 |
Physiological, clinical and therapeutical basis of a new hypothesis for headache.
Topics: Amphetamines; Autonomic Nervous System; Headache; Humans; Levodopa; Methylphenidate; Mianserin; Nomi | 1980 |